This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Repligen Reports Preliminary Financial Results For The Quarter And Nine-Month Fiscal Period Ended December 31, 2011

Repligen Corporation (NASDAQ:RGEN) today reported preliminary financial results for the quarter and nine-month fiscal period ended December 31, 2011. These results reflect significant accomplishments of the Company during the period, highlighted by the completion of our acquisition of Novozymes Biopharma Sweden AB on December 20, 2011 and the successful filing of the Company’s first new drug application (NDA) for SecreFlo™ on December 21, 2011. These preliminary results include estimates of the results of operations from December 21- December 31, 2011 for our new subsidiary Repligen Sweden AB (previously Novozymes Biopharma Sweden AB), but exclude any purchase accounting adjustments associated with the acquisition. The Company was able to acquire the net assets of Novozymes Biopharma Sweden AB at a purchase price significantly below the fair market value of the acquired net assets, thus the Company anticipates recording a gain on bargain purchase once purchase accounting is completed.

Total revenue for the quarter ended December 31, 2011 is expected to be approximately $7.2 million compared to total revenue of $7.1 million for the quarter ended December 31, 2010. Bioprocessing product revenue for the quarter ended December 31, 2011 is anticipated to be $3.1 million, the same as bioprocessing revenue for the quarter ended December 31, 2010. Royalty and research revenue for the quarter ended December 31, 2011 is expected to be approximately $4.1 million compared to $3.9 million for the quarter ended December 31, 2010. Repligen Sweden AB did not record material revenues during the post-acquisition period as the transaction closed just prior to year end.

Operating expenses for the quarter ended December 31, 2011 are expected to be in the range of $9.2 to $9.7 million compared to operating expenses of $6.8 million for the quarter ended December 31, 2010. Net loss for the quarter ended December 31, 2011, before accounting for any potential gain on acquisition, is expected to be in the range of $2.0 to $2.5 million, compared to net income of $376,000 for the quarter ended December 31, 2010.

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,040.37 +29.69 0.16%
S&P 500 2,111.73 +4.34 0.21%
NASDAQ 5,082.9290 +12.9030 0.25%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs